Rational development of a tuberculosis vaccine: From drawing board to clinical trial
Research report (imported) 2015 - Max Planck Institute for Infection Biology
Tuberculosis (TB) remains a global health threat and a new vaccine is urgently needed for better control. We have developed a novel TB vaccine with high efficacy and safety profile. The vaccine has proven its safety and immunogenicity in clinical trials in adults and infants in Germany and South Africa. Currently a study with newborns from HIV-infected mothers is ongoing in South Africa, and for 2016 a large study with adults at heightened TB risk is planned in India.